JSR Life Sciences announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization, to be known as KBI Biopharma, to accelerate innovation and growth of its clients in the global biopharmaceutical sector. The new structure will offer integrated and seamless solutions for all clients, from cell line development and process development to clinical and commercial GMP manufacturing services for mammalian programs.
The streamlined operational approach helps customers accelerate drug development and manufacturing, providing greater flexibility, efficiency, and a simplified experience for partners. By combining the capabilities and expertise of KBI Biopharma and Selexis, customers can reduce manufacturing risks and deliver essential medicines to patients faster.
Also Read: CrowdStrike Introduces Charlotte AI to Deliver Generative AI-Powered Cybersecurity
“The merger of KBI and Selexis into a single business moves KBI into an exciting phase of strategic growth,” said Tim Lowery, President of JSR Life Sciences. “This natural shift in operational strategy is critical for KBI and Selexis customers who have the broad range of capabilities and services to accelerate their evolving drug development and manufacturing needs.”
This combination will allow the KBI’s collective knowledge, scientific expertise and industry-leading technical acumen to be harnessed as an important part of the entire JSR Life Sciences ecosystem. In this way, KBI will become a leading partner for biopharmaceutical companies around the world, and will propel KBI to become a new generation contract development and manufacturing organization (CDMO). Reorganizing and simplifying the operating model to deliver a great experience accelerates innovation for KBI’s global clients and sets them on a strong path to the future.
“The operational consolidation of these two extraordinary companies represents a major change in the way KBI Biopharma will operate in the future,” said JD Mowery, CEO of KBI Biopharma. “By providing fully integrated solutions for our customers, we will be a strengthened partner that can help each of them achieve their goals more efficiently.”
Selexis’ proprietary cell line development platform will be referred to as the SUREtechnology Platform. Mowery will continue to lead as CEO of the combined organization. Employees will report entirely to the KBI executive team.
SOURCE: Businesswire